Marijuana Stocks: Why Canopy Growth (TSX:WEED) Is Beating Aurora Cannabis (TSX:ACB)

After years of close competition, Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is clearly way ahead of its #1 competitor. Here’s why

| More on:
little girl in pilot costume playing and dreaming of flying over the sky

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) and Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) are two of the biggest marijuana stocks by revenue and market cap. With a combined $173 million in gross revenue in their most recent quarters, they control the lion’s share of the Canadian medical and recreational pot markets. Both companies are also rising forces on the world stage, leading the group of Canadian companies that are increasingly dominating the global cannabis market.

In light of this, it’s no surprise that Canopy and Aurora have rewarded investors richly over the years, with both companies gobbling up many thousands of percentage points since their IPOs. As two of the fastest-growing companies in a market where even the weakest stocks usually grow revenue by 100% year over year, Canopy and Aurora are high-growth superstars.

However, between the two of them, Canopy is emerging the clear winner, with greater revenue and, recently, superior profitability metrics. After some close quarters that saw Aurora inching close to Canopy, the latter came out decisively ahead this year and hasn’t fallen behind since. Here are the main reasons why:

Canopy’s ever-improving production techniques

One of Canopy’s key advantages lies in its constantly improving production techniques. In its most recent quarter, the company reduced its cost per gram 18% quarter over quarter and an impressive 32% year over year. While Aurora also lowered its cost year over year in Q3, the 7% trimming is nothing compared to Canopy’s 32%. Canopy’s increasing cost efficiency is partially the result of R&D, but also its ever-growing production space, which allows it to take advantage of economies of scale.

Aurora’s disappointing Q3 earnings

Another factor that’s keeping Canopy ahead of Aurora is the fact that Aurora’s Q3 results were widely seen as disappointing. Whereas Canopy’s most recent quarter was perceived as its best ever, leading many to claim the company could hit $1 billion in sales this year, Aurora’s Q3 missed analyst estimates. Granted, when you’re growing at 367% year over year, it’s hard to beat yourself up too much because analysts expected even more, but a miss is still a miss.

Canopy’s cash horde

A final thing Canopy has going for it is a massive $4.1 billion cash horde, which will allow it to pursue big acquisitions for years into the future. This pile of cash is the fruit of last year’s Constellation Brands investment, which was such a major story at the time that it sent the entire cannabis sector on a months-long rally.

So far, Canopy has been reticent to spend its $4 billion, pursuing only a handful of acquisitions this year, such as the $343 million Acreage deal. This may be a sign of wisdom on Canopy’s part, thereby demonstrating that it intends to pursue acquisitions only when they are sure to improve its bottom line. On the other hand, investors will want to see the money put to good use sooner or later, especially since it came from a deal that resulted in significant equity dilution.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »